PharmiWeb.com - Global Pharma News & Resources
07-Mar-2019

4SC AG: 9 upcoming conferences and roadshows

DGAP-News: 4SC AG / Key word(s): Conference

07.03.2019 / 07:30
The issuer is solely responsible for the content of this announcement.


4SC AG: 9 upcoming conferences and roadshows
 

Planegg-Martinsried, Germany, 7 March 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation at upcoming financial and scientific conferences as well as roadshows. 4SC's management and scientists will be available for one-on-one meetings at these events.
 

London Non-Deal Roadshow

18 March 2019
London, United Kingdom
 

Germany Non-Deal Roadshow

20 March 2019
Germany
 

Amsterdam Non-Deal Roadshow

21 March 2019
Amsterdam, The Netherlands
 

American Association for Cancer Research Annual Meeting 2019 (AACR 2019)

29 March - 3 April 2019
Atlanta, USA
 

Boston Non-Deal Roadshow

1 April 2019
Boston, USA
 

New York Non-Deal Roadshow

2 April 2019
New York, USA
 

San Francisco Non-Deal Roadshow

3 April 2019
San Francisco, USA
 

H.C. Wainwright Global Life Sciences Conference

7 - 9 April 2019
London, United Kingdom
 

15th European Association of Dermato-Oncology Congress (EADO 2019)

24 - 27 April 2019
Paris, France
 

- Announcement ends -
 

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises three key drug candidates in various stages of preclinical and clinical development: resminostat, domatinostat (4SC-202) and 4SC-208.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 46 employees as of 30 September 2018 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
 

Contact

4SC
Anna Niedl, Ph.D., CIRO
Corporate Communications & Investor Relations
anna.niedl@4sc.com
+49 89 700763-66

LifeSci Advisors
Hans Herklots
Managing Director
hherklots@lifesciadvisors.com
+41 79 598 7149



07.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
Phone: +49 89 700763-0
Fax: +49 89 700763-29
E-mail: public@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

Editor Details

Last Updated: 07-Mar-2019